Second-line therapy in metastatic renal cell cancer —how do we treat after immuno-oncology drugs?
SummaryThe treatment landscape of metastatic renal cell cancer (mRCC) is rapidly evolving. To date in 2019 twelve drugs are licensed for this indication, two more drugs are awaited to be introduced into our portfolio of treatment options by the end of the year. First-line treatment has robust clinical trial data and is clearly stated by the consensus guidelines. It consists either of a  tyrosine kinase inhibitor (TKI) monotherapy for favorable risk patients—defined by the Heng or IMDC (International mRCC Database Consortium) score—or the immuno-oncology (IO) combination of ipilimumab and nivolumab (Ipi/Niv...
Source: Memo - Magazine of European Medical Oncology - November 14, 2019 Category: Cancer & Oncology Source Type: research

Management of nonmetastatic muscle invasive bladder cancer in the elderly
SummaryA  substantial increase in the number of elderly patients with muscle invasive bladder cancer (MIBC) is expected in upcoming years due to demographic changes and the peak incidence of bladder cancer in the 8th decade of life. The management of these patients is mainly driven by chronological age, co morbidities, tumor characteristics (unifocality, multifocality, concomitant carcinoma in situ, depth of invasion) and the presence of tumor-related symptoms (hematuria, pain, bladder dysfunction). A potential algorithm for the treatment of elderly patients with MIBC is presented. Ideally these pati ents ar...
Source: Memo - Magazine of European Medical Oncology - November 14, 2019 Category: Cancer & Oncology Source Type: research

Epidemiology of polycythemia vera in a Mexican population
In conclusion, epidemiology of PV in Mexican population is similar to that reported in Western studies, but with more venous thrombosis at diagnosis and a higher incidence of vascular complications postdiagnosis. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 14, 2019 Category: Cancer & Oncology Source Type: research

ASCO 2019: highlights in HER2-positive metastatic breast cancer
In this study a clinically meaningful prolongation of PFS by 2.2 months was observed. In addition, the time to intervention for brain metastases was prolonged in the neratinib group and the cumulative incidence of brain metastases was lower as well. On the downside a high rate of grade 2 and  3 diarrhoea was observed. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 12, 2019 Category: Cancer & Oncology Source Type: research

Evidence-based follow-up in renal cell carcinoma
SummaryThe optimal surveillance strategy in renal cell carcinoma after curative resection or ablation is a field of ongoing research. This review discusses the evidence behind routine follow up, duration of follow up, imaging modality and intervals as well as surveillance after local ablative therapy. The recommendations and differences of major guidelines are outlined as well. A  risk based approach is advocated taking into account both tumor and patient specific characteristics. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - November 11, 2019 Category: Cancer & Oncology Source Type: research

Molecular profiling in gastroesophageal cancer —clinical routine and future perspective
SummaryAlthough several large clinical trials have been conducted in order to investigate targeted inhibition of several molecular pathways in gastric cancer, only a  limited number of targeted therapies have been introduced in clinical routine. Besides scientific interest, international guidelines recommend investigation of some distinct molecular alterations, which are associated with therapeutic consequences. These are (i) human epidermal growth factor rece ptor 2 (HER2), (ii) programmed death receptor 1 (PD-L1) and (iii) microsatellite instability (MSI). There are some emerging markers, such as Epst...
Source: Memo - Magazine of European Medical Oncology - November 8, 2019 Category: Cancer & Oncology Source Type: research

Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria
SummaryThe purpose of this observational study was to determine the prevalence of comorbid conditions in cancer patients with solid tumours selected for specific treatment at 12  divisions of medical oncology in Austria. Data from 1137 patients were collected using a standardized questionnaire; of these, 1036 datasets were evaluable for further analysis. Data were prospectively collected from patients during an in- or outpatient hospital visit over a 4-month period in 20 11. Of these patients 42% had gastrointestinal cancer, 31% had breast cancer, 9% lung cancer and the remaining had urogenital cancer, sarco...
Source: Memo - Magazine of European Medical Oncology - November 6, 2019 Category: Cancer & Oncology Source Type: research

Current trends in small cell lung cancer management —ASCO 2019 update
SummaryDuring the last 30  years the developments in small cell lung cancer (SCLC) have been extremely scarce. Concurrent chemo-radiation associated with prophylactic cranial irradiation in case of complete clinical remission is standard in limited disease. In extensive disease, platinum/etoposide and topotecan remain the s tandard systemic approaches in the first- and second-line setting, respectively. The only notable improvement was communicated in the IMpower133 trial, by the addition of atezolizumab to the platinum/etoposide chemotherapy backbone. Against this background, the current article aims to review the mo...
Source: Memo - Magazine of European Medical Oncology - November 6, 2019 Category: Cancer & Oncology Source Type: research

Targeted therapy in lung cancer —ASCO 2019 update
SummaryNew targeted therapies for patients with non small cell lung cancer were presented at this year ’s ASCO.EGFR exon 20 insertions might soon be treatable with TAK-788, which showed an objective response rate (ORR) of between 25 and 56% with a disease control rate (DCR) between 67 and 100% depending on the presence or absence of brain metastases at baseline. Capmatinib and tepotinib showed durable responses inMET exon 14 mutations as presented in the phase II GEOMETRY trial and the VISION trial. The median duration of response (DOR) was 9.7 months with a median progression free survival (PFS) of 5.42 months in pr...
Source: Memo - Magazine of European Medical Oncology - November 6, 2019 Category: Cancer & Oncology Source Type: research

Advanced/metastatic urothelial carcinoma of the bladder and upper urinary tract
SummaryThree important oral presentations from the ASCO 2019 congress concerning advanced and metastatic urothelial carcinoma of the urinary bladder and the upper tract are highlighted and their potential clinical implications for the improvement of systemic therapies in respective patients are discussed. Enfortumab vedotin, an antibody-drug conjugate targeting nectin ‑4, demonstrated a clinically meaningful objective response rate in patients with prior platinum-based chemotherapy and checkpoint inhibition, in a phase II trial. A high unmet need in this heavily pretreated patient population combined ...
Source: Memo - Magazine of European Medical Oncology - October 28, 2019 Category: Cancer & Oncology Source Type: research

Evidence-based follow-up for breast cancer
In conclusion, breast cancer survivors require comprehensive follow-up management based on evidence, whenever possible. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 24, 2019 Category: Cancer & Oncology Source Type: research

Neoadjuvant therapy in urothelial cancer
SummaryNeoadjuvant cisplatin-based chemotherapy is standard treatment for muscle-invasive bladder cancer before radical cystectomy (RC). Despite level  1 evidence demonstrating an overall survival benefit for patients undergoing RC after neoadjuvant chemotherapy (NAC), acceptance rates are still low. In high-risk upper tract urothelial cancer (UTUC), cumulative evidence suggests that NAC for locally advanced UTUC can improve oncological outcome. Ongoing phase 3 trials will finally prove the benefit or futility of NAC in this tumor entity. Since urothelial cancer (UC) is a heterogeneous disease, pre...
Source: Memo - Magazine of European Medical Oncology - October 23, 2019 Category: Cancer & Oncology Source Type: research

Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer
SummaryEarly stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 15, 2019 Category: Cancer & Oncology Source Type: research

Nonmuscle invasive urothelial cancer — Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
SummaryTo date, intravesical instillation of Bacillus Calmette –Guérin (BCG) is the standard adjuvant treatment for most intermediate- and all high-risk bladder nonmuscle invasive urothelial carcinomas (NMIBC) after complete transurethral resection. Although BCG immunotherapy successfully reduces both recurrence and progression rates in affected patients, th ere are certain limitations associated with its application. Major issues are the relatively high failure rate in up to 40% of patients, the adverse effects of the instillations, and the shortage in BCG supply, requiring concerted alternative strategies. F...
Source: Memo - Magazine of European Medical Oncology - September 27, 2019 Category: Cancer & Oncology Source Type: research

CML at the 2018 ASH meeting —selected presentations
SummaryTreatment recommendations in chronic myeloid leukemia (CML) treatment have not changed substantially since treatment-free remission (TFR) has become a therapeutic option. Hence, allowing more patients to enter TFR is gaining significance. Although, Asciminib as a first-in-class new type of tyrosine kinase inhibitor (TKI) is in clinical development, currently combination treatment with TKIs and Interferon-alpha2b appears the best option to deepen molecular response and broaden the basis of potential TFR candidates. Improving the chances of a first successful TFR has to be the primary goal in TFR optimization as even ...
Source: Memo - Magazine of European Medical Oncology - September 20, 2019 Category: Cancer & Oncology Source Type: research

Highlights on chronic lymphocytic leukemia presented at the 2018  American Society of Hematology Meeting
SummaryChronic lymphocytic leukemia (CLL) treatment strategies have improved and changed dramatically in the last few years. Insights presented at the last American Society of Hematology meeting changed standards of care in the first-line treatment. In patients
Source: Memo - Magazine of European Medical Oncology - September 17, 2019 Category: Cancer & Oncology Source Type: research

Colorectal cancer screening and prevention —pros and cons
SummaryColorectal cancer (CRC) is one of the most frequent cancer entities worldwide and a  leading cause of death. The disease is known to develop from potentially curable, premalignant lesions over several years and therefore is suitable for screening procedures and preventive measures. Several trials have demonstrated reduced incidence and mortality in screening cohorts. A multitude of different screening strategies for CRC have been implemented in different parts of the world. While randomized controlled studies directly comparing screening procedures are still ongoing, colonoscopy remains the gold standard f...
Source: Memo - Magazine of European Medical Oncology - September 13, 2019 Category: Cancer & Oncology Source Type: research

Post San Antonio
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2019 Category: Cancer & Oncology Source Type: research

Screening and prophylaxis of cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2019 Category: Cancer & Oncology Source Type: research

Immunosuppression and its complications
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2019 Category: Cancer & Oncology Source Type: research

News from ASH 2018 —how can we afford innovation in the future?
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2019 Category: Cancer & Oncology Source Type: research

PSA screening —a matter of debate?
SummaryProstate cancer (PCa) is the most common cancer type in men. Overall, the goal of prostate-specific antigen (PSA)-based screening is to identify early-stage disease that can be treated successfully. However, evidence supporting an overall survival advantage in men undergoing PSA screening is controversial, leading to a lack of consensus on guidelines.The present review article provides an overview of the most important studies on PSA screening including the latest updates of large trials. In addition, modern concepts in early detection of PCa that can be added to PSA measurement alone such as PSA isoforms or mpMRI a...
Source: Memo - Magazine of European Medical Oncology - August 28, 2019 Category: Cancer & Oncology Source Type: research

HIV-triggered lymphoma
SummaryTreatment outcomes of AIDS-related lymphomas (acquired immune deficiency syndrome, ARL) have improved, nearing those reported for HIV-negative (human immunodeficiency virus) cohorts; recommended treatment protocols are herewith presented. The diagnostic approach to lymphoma in patients with HIV should include screening for and treatment of concomitant infections attributed to HIV-related immunosuppression. Appropriate antiretroviral treatment with adjustments for potential drug interactions should be initiated urgently, and recommended antibiotic, antifungal and antiviral prophylaxis commenced. (Source: Memo - Magaz...
Source: Memo - Magazine of European Medical Oncology - August 15, 2019 Category: Cancer & Oncology Source Type: research

Systemic treatment of metastatic breast cancer: SABCS 2018
SummaryThis review summarizes clinically relevant trials in metastatic breast cancer (MBC) presented at the 2018 San Antonio Breast Cancer Symposium (SABCS). At the meeting updates of two large phase  III studies were presented: (1) the biomarker analysis of IMpassion130, trying to define the target population for the checkpoint inhibitor atezolizumab in triple-negative MBC and (2) a subgroup analysis of SOLAR-1, where the efficacy and safety of the alpha-specific Phosphoinositide 3(PI3)-kinas e inhibitor alpelisib in combination with fulvestrant was investigated in patients with hormone receptor positive (HR+), ...
Source: Memo - Magazine of European Medical Oncology - August 15, 2019 Category: Cancer & Oncology Source Type: research

ASH 2018 —Highlights in Multiple Myeloma
SummaryMore than 900  abstracts on multiple myeloma were presented at this year’s ASH in San Diego. Several trials explored the addition of the monoclonal antibody daratumumab to established treatment regimens in both newly diagnosed as well as relapsed and refractory multiple myeloma. A long-awaited study tried to evaluate the role of double autologous stem cell transplant in multiple myeloma in newly diagnosed transplant eligible multiple myeloma. In relapsed and refractory multiple myeloma updates from several large trials like CASTOR and POLLUX were presented. Another spotlight were lenalidomide-refract...
Source: Memo - Magazine of European Medical Oncology - August 12, 2019 Category: Cancer & Oncology Source Type: research

A  wearable cardioverter defibrillator for prevention of sudden cardiac death in a hematologic patient—a case report
SummaryThe wearable cardioverter defibrillator (WCD) is a  suitable option to overcome life-threatening episodes of malignant arrhythmia. There is much experience in the use of these devices in patients with idiopathic arrhythmia as well as in patients at a high risk for sudden cardiac death. However, there is lack of experience with WCD usage in hematol ogic patients with a limited expected lifespan. Here, we report a rare case of malignant arrhythmia in a patient with cardiac relapse of diffuse large B‑cell lymphoma (DLBCL) and the option of WCD use. WCD provides the possibility of bridging to ...
Source: Memo - Magazine of European Medical Oncology - August 7, 2019 Category: Cancer & Oncology Source Type: research

Report from the ASCO 2019 Congress, Chicago, May 31st – June 4th 2019
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 2, 2019 Category: Cancer & Oncology Source Type: research

Cure is not enough! Why it is time to act and close the gap
ConclusionThe Childhood Cancer International Europe Survivors Network call for action: We need the support of politicians and our health care systems to make sure that every single survivor gets the long-term care that they need. So #RaiseYourHands4Survivors and help us close the gap! (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 2, 2019 Category: Cancer & Oncology Source Type: research

ASH 2018 —aggressive lymphoma
SummaryAt the American Society of Hematology Meeting (ASH) 2018 promising data were presented reflecting the impressing advances of clinical research in aggressive lymphoma. Besides promising and partially practice-changing therapies in first-line treatment, there was a  focus on Chimeric Antigen Receptor T Cell (CART) therapy for patients with relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL): longer follow-up, real world data and new developments were reported. A bit overshadowed by CART therapy hype promising data for adding venetoclax to chemoi mmuntherapy, bispecific antibodies, antibody d...
Source: Memo - Magazine of European Medical Oncology - July 30, 2019 Category: Cancer & Oncology Source Type: research

Post San Antonio Breast Cancer Symposium 2018
SummaryThis short review summarizes the most important facts presented at the San Antonio Breast Cancer Symposium 2018 concerning local therapy of breast cancer, including breast and lymph node surgery as well as radiotherapy. Despite the increasing use of neoadjuvant chemotherapy (nCHT) and consequently higher response and pathologic complete response (pCR) rates in the past years, breast-conserving surgery (BCS) has not increased. This is not only due to positive genetic testing, but it is mostly based on patients ’ preference. On the other hand, quality of life seems to be better in young patients undergoing BCS r...
Source: Memo - Magazine of European Medical Oncology - July 25, 2019 Category: Cancer & Oncology Source Type: research

Cutaneous melanoma —The benefit of screening and preventive measures
SummaryThe incidence rates of cutaneous melanoma are continually rising in the Caucasian population with the highest rates in Australia and New Zealand. The genesis of melanoma is a  complex interplay between genetic predisposition and exogenous factors. The major known exogenous risk factor of this potentially lethal malignancy is ultraviolet (UV) radiation. In the last decades diverse prevention strategies have been developed which in case of primary prevention are aimed to protect the skin from high-dose UV radiation. Although its effect is only visible after a long period of time and despite the growing aware...
Source: Memo - Magazine of European Medical Oncology - July 25, 2019 Category: Cancer & Oncology Source Type: research

Checkpoint inhibitors in head and neck cancer
SummaryHead and neck cancer (HNC) are aggressive cancers and represents the sixth leading cancer by incidence worldwide. This kind of cancer constitutes about 3% of all newly diagnosed malignant tumors in humans, and this percentage is likely to increase in the future. Most common available treatment methods which include surgery, radiotherapy, and chemotherapy are associated with low survival outcomes in combination with substantial toxicities emphasize the necessity for novel treatment strategies.The combination immunotherapies represent a fundamental step in the progress towards improving responses, and immune checkpoin...
Source: Memo - Magazine of European Medical Oncology - July 17, 2019 Category: Cancer & Oncology Source Type: research

Post San Antonio: immunotherapy, chemotherapy and new combinations
This article gives a summary of several studies presented at the San Antonio Breast Cancer Symposium in 2018. In specific, the biomarker analysis of the ‘IMpassion130’ trial, the effects of CDK4/6 inhibitors on T-cells and tumor immunogenicity, adjuvant chemotherapy in older patients, the prognostic relevance of achieving a pathologic complete response after neoadjuvant therapy, the quality of life analysis of the ‘TAILORx’ trial, the progno stic impact of detecting bone marrow tumor cells at the time of primary resection and b-cell lymphoma 2 as a new possible therapeutic target in luminal breast c...
Source: Memo - Magazine of European Medical Oncology - July 16, 2019 Category: Cancer & Oncology Source Type: research

Risk of cancer after long-term  therapy of autoimmune disorders with glucocorticoids or DMARDs—a controversial issue
SummaryMost autoimmune diseases like RA (rheumatoid arthritis) are usually associated with lifelong treatment. The etiology of RA remains unclear, but it depends on a  high-risk genetic background and an environmental trigger, which leads to autoimmune dysregulation and results in autoinflammation. This process preferentially affects joints but may spread to different organs and systems. Several studies have illustrated that patients with RA have an increased ov erall incidence of malignancy compared to the general population (risk of 5–10%). However, it remains unclear if biological agents like DMARDs (disease-...
Source: Memo - Magazine of European Medical Oncology - July 12, 2019 Category: Cancer & Oncology Source Type: research

Immunosuppression after renal transplantation
SummaryImmunosuppression (IS) is administered to kidney transplant recipients to prevent rejection episodes and loss of the renal allograft. Most centers rely on a triple IS after induction with either interleukin ‑2 receptor antibodies or antithymocyte globulin. The most frequently used substances for maintenance IS are glucocorticoids, antimetabolites, mTOR inhibitors (mTORi), calcineurin inhibitors (CNI) and the costimulation blocker belatacept. Guidelines recommend a triple combination consisting of CNI s, antimetabolites and corticosteroids for the majority of patients. The long-term risk for malignancy in general i...
Source: Memo - Magazine of European Medical Oncology - July 10, 2019 Category: Cancer & Oncology Source Type: research

Skin tumours in organ transplant recipients —implications for the plastic surgeon
SummarySquamous cell carcinoma of the skin (SCC) and basal cell carcinoma (BCC) are common entities, often with a  benign course. Tumour biology, however, is different in immunosuppressed individuals, such as organ transplant recipients (OTR). As immunosuppression-sparing protocols have not yet been successfully introduced to the clinics, nonmelanoma skin cancers (NMSCs) will continue to affect a majority of OTR, leading to significant morbidity and mortality. Interdisciplinary treatment including the transplant physician, dermatologist and the plastic surgeon is warranted for optimal patient management. This rev...
Source: Memo - Magazine of European Medical Oncology - July 1, 2019 Category: Cancer & Oncology Source Type: research

Giant leiomyoma of the renal capsule: CT and MR imaging features with pathologic correlations
SummaryRenal leiomyoma (RL) is a  rare benign tumor, usually presenting as a small asymptomatic lesion, frequently found during autopsy with a higher incidence in women (2:1). However, larger RL can become symptomatic and show structural changes (such as hemorrhagic and cystic degeneration), thus posing a diagnostic challenge. A 49-year-old woman with a recent history of weight loss and left flank pain was referred to our institution. An ultrasound exam revealed the presence of a complex mass at the left kidney. Both CT and MRI scans were performed to characterize the renal mass, which ap...
Source: Memo - Magazine of European Medical Oncology - June 26, 2019 Category: Cancer & Oncology Source Type: research

Lung cancer screening —the surgeon’s perspective
This article provides a view on lung cancer screening from a thoracic surgeon ’s perspective. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 18, 2019 Category: Cancer & Oncology Source Type: research

Immunotherapeutic approach to a  case of advanced hepatoid adenocarcinoma of the lung
Conclusion and outlookThe case presented here is of interest as it adopts a  novel immunotherapeutic approach to HAC, yielding a promising outcome. This highlights the importance of molecular typing and immunohistochemical profiling in the diagnosis and management of non-small cell lung cancer. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 12, 2019 Category: Cancer & Oncology Source Type: research

Head and neck Langerhans cell histiocytosis: two case reports and review of the literature
We present 2 cases of unifocal single system LCH located at the mandible and skull base, and describe the diagnostic work up and treatment. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 12, 2019 Category: Cancer & Oncology Source Type: research

Resistance to anti-hormonal therapy in prostate cancer
SummaryAdvanced stage prostate cancer is frequently treated with androgen receptor antagonists. Improvement in patients ’ survival has been achieved with the anti-androgen enzalutamide. However, there may be an increasing number of point mutations of the androgen receptor during therapy. In addition, ligand-independent activation of truncated androgen receptors may occur during anti-hormonal therapy. In prostate ca ncer, there is also an increased expression of coactivators and decreased expression of corepressors, thus, contributing to the disease progression. Stromal factors such as interleukins also contribute to ...
Source: Memo - Magazine of European Medical Oncology - June 12, 2019 Category: Cancer & Oncology Source Type: research

Whom to screen? A  view on lung cancer screening from the pneumologist’s perspective
This article gives a  short overview on participant selection in the NLST and NELSON trials, and on current evidence for implementation of multivariable risk prediction models. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 5, 2019 Category: Cancer & Oncology Source Type: research

Saving lives with lung cancer screening
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 1, 2019 Category: Cancer & Oncology Source Type: research

Overcoming resistance and bypassing checkpoints —possible new therapeutic frontiers in oncology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 1, 2019 Category: Cancer & Oncology Source Type: research

Response assessment in non-small cell lung cancer immunotherapy: initial experiences in utilizing FDG PET/CT and the PD-1 blocker nivolumab
ConclusionsThe findings indicate that the PERCIST-based evaluation could identify progressive disease earlier. Early identification of nonresponders could lead to prevention of overtreatment and to an early switch to a  more effective therapy. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 29, 2019 Category: Cancer & Oncology Source Type: research

Report from the ELCC 2019 Congress, Geneva, April 10th-13th, 2019
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 24, 2019 Category: Cancer & Oncology Source Type: research

Correction to: Seasonal fever for 11 years! A  presentation of hemophagocytic lymphohistiocytosis secondary to marginal zone lymphoma
Correction to:memo 2019https://doi.org/10.1007/s12254-019-0487-4The original version of this article unfortunately contained a  mistake.The spelling of the last author ’s name is “Prerna Mewawalla”.The original article has been … (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 23, 2019 Category: Cancer & Oncology Source Type: research

Update in thrombosis and hemostasis: ASH meeting 2018
SummaryIn the field of thrombosis and hemostasis the focus was laid on the prophylaxis and treatment of venous thromboembolism in patients with active cancer during this years ’ meeting of the American Society of Hematology (ASH) in San Diego. The Adam-VTE trial completed the series of studies using Xa-antagonists for the treatment of cancer-associated thromboembolism. Apixaban reduced the number of recurrent thromboembolic events compared to treatment with dalteparin w ithout increasing the bleeding risk. Furthermore, the use of a prophylactic dose of rivaroxaban or apixaban showed positive results in the prima...
Source: Memo - Magazine of European Medical Oncology - May 17, 2019 Category: Cancer & Oncology Source Type: research

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches
SummaryImmuno-oncology and in particular checkpoint inhibitor (CPI) treatment has become a  novel promising cancer therapy strategy in recent years. However, still a minority of patients respond to checkpoint blockade. Primary and secondary resistance to CPI is a challenge in the daily clinical routine. Combination strategies have been tested in various clinical trials in order to addr ess this issue. Data available from these trials indicate improved activity depending on the tumor type. This review article focuses on the molecular background for resistance to CPI, gives an overview of current clinical data...
Source: Memo - Magazine of European Medical Oncology - May 17, 2019 Category: Cancer & Oncology Source Type: research

Lung cancer screening from the oncologist ’s perspective
This article provides a view on lung cancer screening from an oncologist’s perspective. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - May 17, 2019 Category: Cancer & Oncology Source Type: research